strong evidence that the bleeding is from another site. It may therefore be appropriate to endoscope urgently only those patients in whom the spleen is palpable, while endoscopy could reasonably be postponed when the spleen is impalpable. This may be particularly appropriate in hospitals where experienced endoscopists are not on immediate recall.
In our study 27%" of those who bled did so from a site other than their varices. This agrees with other British studies-and also confirms that this group is smaller than in North America, where more patients bleed from gastric erosions. The relationships between the height of the portal venous pressure, the presence and size of oesophageal varices, bleeding from the varices, and the size of the spleen are not clear (figure) . Oesophageal varices seen on barium swallow examination are more likely to bleed if they are large2 but, surprisingly, the portal pressure is poorly correlated with the size of varices,2 3 with the occurrence of bleeding,4 or with the size of the spleen. Hypercalcaemia occasionally occurs as an acute event in patients with advanced breast cancer after hormone treatment.' Tamoxifen, a nonsteroidal oestrogen antagonist, is widely used for advanced breast cancer,2 and over the past two years we have treated 62 such patients with tamoxifen. We describe the course of four patients who became hypercalcaemic after starting tamoxifen.
Case reports Case 1-A 57-year-old woman was admitted with advanced breast cancer and bone metastases. Tumour oestrogen receptor concentration was 95 fmol (2 bfg)/mg protein and serum calcium concentration was normal. Tamoxifen was given (20 mg twice daily), and after four days she complained of nausea, vomiting, and weakness. Her serum calcium concentration was 4-0 mmol/i (16 2 mg/100 ml). Tamoxifen was discontinued and she was treated with intravenous fluids and steroids. A few days later serum calcium concentration was 2-7 mmol/l (10-6 mg/100 ml). Tamoxifen was reinstituted after 10 days. Five months later serum calcium concentration was normal, she was symptom-free, and radiography showed sclerosis of previous lytic lesions.
Case 2-A 61-year-old woman was admitted with a mass in the breast and widespread osteolytic metastases. Tumour oestrogen receptor concentration was 381 fmol (103-8 fg)/mg protein and serum calcium concentration was normal. Tamoxifen was given (10 mg twice daily), and after four days she became confused. Serum calcium concentration was 2-9 mmol/l (11-5 mg/100 ml). Tamoxifen was discontinued and she was treated with fluids and prednisone. Three days later her condition was improved. Her serum calcium concentration was 2-5 mmol/l (10-2 mg/100 ml). Cytotoxic chemotherapy was tried and achieved temporary control.
Case 3-A 68-year-old woman with breast cancer and bone metastases was admitted because of confusion and vomiting. Serum calcium concentration was 3 mmol/l (12-3 mg/100 ml) but was normal after administration of fluids and prednisone. Tamoxifen was given (20 mg twice daily), and after five days she developed weakness, and serum calcium concentration had risen to 3 0 mmol/l (12-0 mg/100 ml). Tamoxifen was stopped, and serum calcium concentration fell to 2-5 mmol/l (9-8 mg/100 ml) after fluids and steroids were administered. Cytotoxic chemotherapy was given but without response.
Case 4-A 60-year-old woman presented with stage IV breast cancer and pulmonary and bone metastases. Serum calcium concentration was normal. Tamoxifen, 20 mg twice daily, and intermittent adriamycin and cyclophosphamide were given, and two weeks later she developed confusion and bone pain. Serum calcium concentration was 3-7 mmol/I (15-0 mg/100 ml) but became normal when she was treated with fluids, diuretics, prednisone, and oral phosphate. Her bone pains disappeared. Two months later radiography showed sclerosis of the bone metastases. Tamoxifen, adriamycin, and cyclophosphamide were continued throughout this period.
Comment
Four out of 26 patients with breast cancer and bone metastases developed acute hypercalcaemia when treated with tamoxifen (figure). We believe that hypercalcaemia after tamoxifen may signify tumour response and be a reason for continuing with tamoxifen and treating the hypercalcaemia. This is supported by a report of tamoxifen "flare" in metastatic breast cancer and the observation that acute exacerbation of bone pain in patients with breast cancer after tamoxifen may be associated with tumour response.'5 The mechanism of tamoxifeninduced tumour response needs further investigation, since acute hypercalcaemia is not seen in patients responding to chemotherapy or oophorectomy.
Requests for reprints should be sent to Professor M H N Tattersall.
Kennedy, B J, et al, Cancer Research, 1953, 13, 455. 2Kiang Hydrallazine-induced SLE-like syndrome presenting as a leg ulcer
The use of hydrallazine for systemic hypertension may be complicated by a syndrome resembling systemic lupus erythematosus (SLE) in 10-15",, of patients after cumulative doses exceeding 100 g.' We describe a patient who presented with a painful leg ulcer.
Case report
A 50-year-old man admitted in January 1979 had a nine-week history of a painful ulcer above the right heel, which had steadily enlarged and prevented walking. He had a nine-month history of symptoms suggestive of Raynaud's phenomenon, joint pains for three months, malaise for six weeks, and an itchy rash over the left shin and forearm for one week. Malignant hypertension was diagnosed in 1970 (blood pressure 250/130 mm Hg) and treatment instituted with debrisoquine. In 1976 he was admitted with a blood pressure of 270/180 mm Hg and hydrallazine treatment was begun (150 mg daily). There was no diabetes mellitus, vascular insufficiency, or trauma. He smoked 15 cigarettes daily.
He was drowsy, with mild tachycardia (100/min) and low-grade fever (37 5 C). Blood pressure was 220/150 mm Hg (supine) and 190/135 mm Hg (erect). The ulcer (3-5 cm diameter), directly over the right tendo Achillis, wvas superficial, but the edge was discoloured and the base encrusted with old blood. There was no arterial or venous insufficiency or regional lymphadenopathy. There was severe wasting of the right quadriceps muscle, equinus deformity of the right ankle, and a diffuse purpuric rash over the left shin and forearm.
Haemoglobin concentration was 12 8 g/'dl but white cell and platelet counts were normal. Plasma viscosity was raised (1-92 mPa s; 1-92 cp), serum iron concentration 6 9 [emol l (38 5 fLg,100 ml), total iron-binding capacity 47 ,umol/l (262 5 zg, 100 ml), blood urea concentration 8 1 mmolj'l (48 6 mg/100 ml), and creatinine clearance 52 mljmin. Titre for antinuclear factor (ANF) was 1/320 and DNA antibody binding 21 110. IgM concentration was 9 0 g 1, but complement values were normal. Random blood glucose estimations, chest and ankle radiographs, and Wassermann and latex fixation tests showed no abnormalities. The patient was a slow acetylator as assessed by sulphadimidine clearance. A biopsy specimen of the ulcer disclosed fibrosing granulation tissue. All these features suggested that an SLE-like syndrome may have caused this patient's indolent ulcer. Since total hydrallazine exposure may have been relevant the drug was replaced by atenolol and bendrofluazide. With bed rest, raising the leg, and cleaning the ulcer locally his condition rapidly improved. The rash disappeared five days after stopping hydrallazine, and by one week the ulcer was healing; this was accelerated by applying split-skin grafts. At discharge plasma v-iscosity was 1-7 mPa s (1 7 cp). After four months he was in good health and had returned to work. The ulcer had healed, and after physiotherapy his ankle and thigh had returned to normal. Blood pressure was controlled at 140/90 mm Hg. Plasma viscosity, ANF titres, and DNA antibody binding were unchanged.
Comment
Dubois2 reviewed 520 cases of idiopathic SLE and found a 5% incidence of leg ulceration but this complication has not been reported in hydrallazine-induced SLE. About 1000 of cases of SLE may be caused by drugs, notably hydrallazine. Patients may develop a positive ANF titre with hydrallazine without having SLE-like symptoms.' This phenomenon was also shown for prazosin.4 Druginduced SLE differs from idiopathic SLE in affecting older people, relatively more men, and the lung and kidney less often; DNA antibody binding is under 301 .3 Some 960) of patients with druginduced SLE are slow acetylators.:' 5 Although first described in patients taking large daily doses of hydrallazine (400 mg),3 the syndrome may occur with lower doses (150 mg)5; the cumulative dosage appears to be more important. Symptoms usually disappear within four months of stopping hydrallazine, but ANF titres and DNA antibody binding may take up to six years to return to normal.5
The relation between toxic symptoms and hypertensive control is not clear. Perry3 suggested that toxicity was associated with control of blood pressure and that suddenly stopping treatment led to rebound hypertension. In our case toxicity was associated with failure of hypertensive control. We suggest that acetylator states of all patients taking long-term hydrallazine should be determined to identify those at risk from drug-induced SLE. Once hypertension is controlled the daily dose should be reduced to the minimum needed to maintain normal blood pressure. Gallium-67 scanning in pyrexia of unknown origin Pyrexia of unknown origin (PUO) is a common problem in clinical medicine, occurring either as a presenting feature or as a postoperative complication. We have assessed the efficacy of 7Ga scanning as a non-invasive investigation of PUO.
Methods and results
Wc reviewed retrospectively 67 consecutive scans performed on 61 patients with PUO referred to our department in one year. The PUO had been prcsent for several days to several weeks, and routine investigations including blood, sputum, and urine cultures, chest radiography, and intravenous urography, had not determined its origin. Imaging was performed 48 and 72 hours aftcr intravenous injection of 75-100 MBq (2-2-7 mCi) gallium citrate ('7Ga; Radiochemical Centre). Patients were not preparcd before injection, but unless contraindicated Dorbanex tablets (danthronpoloxamer) wvere given 12-hourly for 72 hours afterwards. Imaging was performed with an Ohio Nuclear 84 double-hcaded rectilinear scanner with 5 :1 ratio minification using a high-energy collimator and an analyser setting that accepted the 185 and 296 keV peaks of 6 7Ga. Patients were imaged from neck to thigh. When indicated, a liver-spleen scan with ssm'Fc-sulphur colloid was performed after the 67Ga scan at 72 hours, the patient being kept in the same position to permit superimposition of the scans. Gallium-67 scans wvere regarded as normal when uptake was seen only in sitcs of physiological accumulation, and abnormal when uptake was seen at other sites, provided relative uptake increased between 48 and 72 hours.
Of the 67 67 Ga scans, 50 were abnormal. Most sites of abnormal uptake were in the abdomen (table), miscellaneous sites consisting mainly of
